Literature DB >> 17726098

Inhibitors of metabolism rescue cell death in Huntington's disease models.

Hemant Varma1, Richard Cheng, Cindy Voisine, Anne C Hart, Brent R Stockwell.   

Abstract

Huntington's disease (HD) is a fatal inherited neurodegenerative disorder. HD is caused by polyglutamine expansions in the huntingtin (htt) protein that result in neuronal loss and contribute to HD pathology. The mechanisms of neuronal loss in HD are elusive, and there is no therapy to alleviate HD. To find small molecules that slow neuronal loss in HD, we screened 1,040 biologically active molecules to identify suppressors of cell death in a neuronal cell culture model of HD. We found that inhibitors of mitochondrial function or glycolysis rescued cell death in this cell culture and in in vivo HD models. These inhibitors prevented cell death by activating prosurvival ERK and AKT signaling but without altering cellular ATP levels. ERK and AKT inhibition through the use of specific chemical inhibitors abrogated the rescue, whereas their activation through the use of growth factors rescued cell death, suggesting that this activation could explain the protective effect of metabolic inhibitors. Both ERK and AKT signaling are disrupted in HD, and activating these pathways is protective in several HD models. Our results reveal a mechanism for activating prosurvival signaling that could be exploited for treating HD and possibly other neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726098      PMCID: PMC1964858          DOI: 10.1073/pnas.0704482104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

Review 1.  Mitochondria: releasing power for life and unleashing the machineries of death.

Authors:  Donald D Newmeyer; Shelagh Ferguson-Miller
Journal:  Cell       Date:  2003-02-21       Impact factor: 41.582

2.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

Authors:  Barbara L Apostol; Katalin Illes; Judit Pallos; Laszlo Bodai; Jun Wu; Andrew Strand; Erik S Schweitzer; James M Olson; Aleksey Kazantsev; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2005-12-05       Impact factor: 6.150

Review 3.  Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Authors:  Lindsay R Pattison; Mark R Kotter; Dean Fraga; Raphael M Bonelli
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

Review 4.  Neurodegenerative conditions associated with ageing: a molecular interplay?

Authors:  Kostoula Troulinaki; Nektarios Tavernarakis
Journal:  Mech Ageing Dev       Date:  2005-01       Impact factor: 5.432

5.  The effects of dietary restriction on mitochondrial dysfunction in aging.

Authors:  R J Feuers
Journal:  Ann N Y Acad Sci       Date:  1998-11-20       Impact factor: 5.691

6.  Effect of sodium fluoride on glycolysis in human erythrocytes and Ehrlich ascites tumour cells in vitro.

Authors:  M Gumińska; J Sterkowicz
Journal:  Acta Biochim Pol       Date:  1976       Impact factor: 2.149

7.  ATP depletion inhibits glucocorticoid-induced thymocyte apoptosis.

Authors:  C Stefanelli; F Bonavita; I Stanic'; G Farruggia; E Falcieri; I Robuffo; C Pignatti; C Muscari; C Rossoni; C Guarnieri; C M Caldarera
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

8.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

9.  Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles.

Authors:  Benjamin R Underwood; David Broadhurst; Warwick B Dunn; David I Ellis; Andrew W Michell; Coralie Vacher; David E Mosedale; Douglas B Kell; Roger A Barker; David J Grainger; David C Rubinsztein
Journal:  Brain       Date:  2006-02-07       Impact factor: 13.501

10.  Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans.

Authors:  Cindy Voisine; Hemant Varma; Nicola Walker; Emily A Bates; Brent R Stockwell; Anne C Hart
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

View more
  28 in total

1.  Meclizine is neuroprotective in models of Huntington's disease.

Authors:  Vishal M Gohil; Nicolas Offner; James A Walker; Sunil A Sheth; Elisa Fossale; James F Gusella; Marcy E MacDonald; Christian Neri; Vamsi K Mootha
Journal:  Hum Mol Genet       Date:  2010-10-25       Impact factor: 6.150

Review 2.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

3.  CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease.

Authors:  Jill R Crittenden; Denise E Dunn; Farhan I Merali; Ben Woodman; Michael Yim; Anna E Borkowska; Matthew P Frosch; Gillian P Bates; David E Housman; Donald C Lo; Ann M Graybiel
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

Review 4.  Animal models of polyglutamine diseases and therapeutic approaches.

Authors:  J Lawrence Marsh; Tamas Lukacsovich; Leslie Michels Thompson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

5.  Socially responsive effects of brain oxidative metabolism on aggression.

Authors:  Hongmei Li-Byarlay; Clare C Rittschof; Jonathan H Massey; Barry R Pittendrigh; Gene E Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 6.  Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.

Authors:  D Allan Butterfield; Miranda L Bader Lange
Journal:  J Neurochem       Date:  2009-09-23       Impact factor: 5.372

7.  Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity.

Authors:  S A Masino; M Kawamura; C D Wasser; C A Wasser; L T Pomeroy; D N Ruskin
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway.

Authors:  Hemant Varma; Ai Yamamoto; Melissa R Sarantos; Robert E Hughes; Brent R Stockwell
Journal:  J Biol Chem       Date:  2010-09-21       Impact factor: 5.157

9.  MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.

Authors:  David M Taylor; Roger Moser; Etienne Régulier; Lionel Breuillaud; Meredith Dixon; Ayshe Ana Beesen; Linda Elliston; Mariana de Fatima Silva Santos; Jinho Kim; Lesley Jones; Darlene R Goldstein; Robert J Ferrante; Ruth Luthi-Carter
Journal:  J Neurosci       Date:  2013-02-06       Impact factor: 6.167

10.  Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.

Authors:  Melissa R Sarantos; Theodora Papanikolaou; Lisa M Ellerby; Robert E Hughes
Journal:  J Huntingtons Dis       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.